UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of March 2022

Commission File Number: 001-39365

Amryt Pharma plc
(Translation of registrant's name into English)

Dept 920a 196 High Road, Wood Green,
London, United Kingdom, N22 8HH

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):       

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):       

 

 

On March 16, 2022, Amryt Pharma plc (“Amryt”) disclosed that the following Amryt board members and executive officers have purchased American Depositary Shares (“ADSs”), each representing five ordinary shares of Amryt, as per the table below. The ADSs were purchased in the open market between March 10 and March 15, 2022.

Name Position Number of ADSs Purchased
Ray Stafford Chairman 10,000
George Hampton Jr Board Director 20,000
Stephen Wills Board Director 7,500
Dr. Alain Munoz Board Director 4,500
Dr. Patrick Vink Board Director 5,000
Dr. Joe Wiley CEO 3,200
Rory Nealon CFO/COO 6,750

 
 
 
 
 
 
 
 
 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Amryt Pharma plc    
  (Registrant)
   
  
Date: March 16, 2022     /s/ Rory Nealon    
  Rory Nealon
  Chief Financial Officer
  
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Amryt Pharma Charts.
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Amryt Pharma Charts.